IN8bio Inc (INAB)
1.105
+0.06
(+6.25%)
USD |
NASDAQ |
May 15, 15:05
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 48.76M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -55.74% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 2.782 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500. |
| URL | https://www.in8bio.com |
| Investor Relations URL | https://investors.in8bio.com/ |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 09, 2024 (est.) |
| Last Earnings Release | May. 09, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500. |
| URL | https://www.in8bio.com |
| Investor Relations URL | https://investors.in8bio.com/ |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Aug. 09, 2024 (est.) |
| Last Earnings Release | May. 09, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |